Trend toward noninferiority trials may mean more difficult interpretation of trial results.

Journal of the National Cancer Institute

Volumn 99, Issue 23, 2007, Pages 1746-1748

  Tuma, Rabiya S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CLINICAL TRIAL; DRUG APPROVAL; DRUG INDUSTRY; FINANCIAL MANAGEMENT; HUMAN; METHODOLOGY; NEOPLASM; NOTE; PATIENT COMPLIANCE; STANDARD; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; DRUG APPROVAL; DRUG INDUSTRY; HUMANS; MARKETING OF HEALTH SERVICES; NEOPLASMS; PATIENT COMPLIANCE; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 38449111304     PISSN: None     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djm258     Document Type: Note

References (0)